This new knowledge provides more options for developing psychedelics into therapeutic drug formulations.
Anorexia has phenomenological parallels to anxiety and addiction, both of which have been shown to improve with psilocybin-assisted interventions.
Psilacetin is less expensive and easier to make than psilocybin.
The answer is yes and no. It's a matter of perspective.
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.